Intervention

Paroxetine

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 23 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials23

Recruiting1

Common conditions21

Lead sponsors shown15

Clinical trials

23 shown

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant TumorsNCT07070232 · 2025-08-12

Paroxetine Safety and Efficacy in Rheumatoid ArthritisNCT06231745 · 2024-01-31

The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes MellitusNCT06203275 · 2024-01-01

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in KoreaNCT04446039 · 2022-07-04

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis PatientsNCT04757571 · 2021-02-01

Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental DisordersNCT04218981 · 2020-01-15

Vortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic AssessmentNCT03779789 · 2019-02-01

Pharmacovigilance in Gerontopsychiatric PatientsNCT02374567 · 2015-01-01

Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression DisorderNCT02273154 · 2014-08-01

Algorithm Guided Treatment Strategies for Major Depressive DisorderNCT01764867 · 2012-06-01

Lithium Versus Paroxetine in Major DepressionNCT01416220 · 2011-09-01

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 GeneNCT02237937 · 2011-09-01

The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled TrialNCT02191124 · 2011-06-01

Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive DisorderNCT01354314 · 2010-11-01

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDDNCT00445679 · 2007-07-01

Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 PathwayNCT00456898 · 2007-01-01

MDD POC Study GSK372475 Subjects Depressive DiseaseNCT00420641 · 2006-12-19

Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive DisorderNCT00351910 · 2006-05-01

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major DepressionNCT00429169 · 2004-06-01

Duloxetine Versus Paroxetine for Major DepressionNCT00489775 · 2004-01-01

Risperidone vs. Paroxetine for Panic AttacksNCT00206765 · 2003-01-01

A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic AttacksNCT00457106 · 2002-06-01

Antidepressant Prophylaxis for Interferon-Induced Depression: Efficacy of ParoxetineNCT00357045

Common conditions

Leading sponsors

Beth Israel Medical Center2 Wyeth is now a wholly owned subsidiary of Pfizer2 AstraZeneca1 aya ramadan ashmawy sarhan1 Azienda Ospedaliera Universitaria Integrata Verona1 BioNTech SE1 Capital Medical University1 Central South University1 Eli Lilly and Company1 GlaxoSmithKline1 Hannover Medical School1 HolsboerMaschmeyer NeuroChemie GmbH1 Johns Hopkins University1 Mostafa Bahaa1 New York State Psychiatric Institute1

Trial status mix

COMPLETED13

UNKNOWN4

TERMINATED3

WITHDRAWN2

RECRUITING1

Phase mix

PHASE48

PHASE36

PHASE25

PHASE14

NA2

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.